The Verge: “The Food and Drug Administration authorized a second at-home antiviral pill to treat COVID-19 on Thursday. The clearance for the drug, called molnupiravir, came a day after the agency signed off on Pfizer’s COVID-19 antiviral, called Paxlovid. Both drugs reduce the risk of hospitalization and death in people diagnosed with COVID-19 and at risk of having a severe case of the disease. Molnupiravir, made by pharmaceutical company Merck, is authorized for people 18 years of age and older who are at a high risk of getting seriously ill if they contract the coronavirus. It’s a higher age cutoff than Paxlovid, which is cleared for people 12 and up, because molnupiravir might affect bone and cartilage growth, the FDA said in a statement. Like Paxlovid, patients have to start taking Merck’s drug within a few days of developing symptoms in order for it to be the most effective. That might be difficult in the United States, where testing to confirm someone has COVID-19 is often slow and limited — particularly during surges in case numbers when treatments are most needed…”